159 related articles for article (PubMed ID: 10592100)
1. 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.
Kralovánszky J; Katona C; Jeney A; Pandi E; Noordhuis P; Erdélyi-Tóth V; Otvös L; Kovács P; Van der Wilt CL; Peters GJ
J Cancer Res Clin Oncol; 1999 Dec; 125(12):675-84. PubMed ID: 10592100
[TBL] [Abstract][Full Text] [Related]
2. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.
Peters GJ; Lankelma J; Kok RM; Noordhuis P; van Groeningen CJ; van der Wilt CL; Meyer S; Pinedo HM
Cancer Chemother Pharmacol; 1993; 31(4):269-76. PubMed ID: 8422689
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M
Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of measuring 5-fluorouracil catabolic potential by oral loading.
Watabe S; Sengoku H; Kawai K; Matsuda M; Sakamoto K; Kamano T
J Int Med Res; 2005; 33(5):501-6. PubMed ID: 16222882
[TBL] [Abstract][Full Text] [Related]
7. Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma.
Kamm YJ; Peters GJ; Hull WE; Punt CJ; Heerschap A
Br J Cancer; 2003 Aug; 89(4):754-62. PubMed ID: 12915890
[TBL] [Abstract][Full Text] [Related]
8. [Potentiation of 5-fluorouracil efficacy. Molecular mechanisms playing a role in the cytotoxic action of 5-fluorouracil and 5-ethyl-2'-deoxyuridine (EUdR) combination].
Katona C; Timár F; Oláh J; Bocsi J; Budai B; Otvös L; Kralovánszky J
Magy Onkol; 2004; 48(3):243-51. PubMed ID: 15520875
[TBL] [Abstract][Full Text] [Related]
9. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
Baccanari DP; Davis ST; Knick VC; Spector T
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11064-8. PubMed ID: 8248211
[TBL] [Abstract][Full Text] [Related]
10. Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.
Codacci-Pisanelli G; van der Wilt CL; Pinedo HM; Franchi F; Noordhuis P; Braakhuis BJ; van Laar JA; Peters GJ
Eur J Cancer; 1995; 31A(9):1517-25. PubMed ID: 7577082
[TBL] [Abstract][Full Text] [Related]
11. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
Saif MW; von Borstel R
Cancer Chemother Pharmacol; 2006 Jul; 58(1):136-42. PubMed ID: 16187114
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
15. Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.
Derissen EJ; Jacobs BA; Huitema AD; Rosing H; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2016 May; 81(5):949-57. PubMed ID: 26718616
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colorectal tumor xenografts.
Kopper L; Magyarosy E; Jeney A; Lapis K; Szabolcs A; Otvös L
Oncology; 1984; 41(3):155-8. PubMed ID: 6328393
[TBL] [Abstract][Full Text] [Related]
17. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Gamelin E; Boisdron-Celle M; Guérin-Meyer V; Delva R; Lortholary A; Genevieve F; Larra F; Ifrah N; Robert J
J Clin Oncol; 1999 Apr; 17(4):1105. PubMed ID: 10561167
[TBL] [Abstract][Full Text] [Related]
18. 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Al Safarjalani ON; Zhou XJ; Rais RH; Shi J; Schinazi RF; Naguib FN; El Kouni MH
Cancer Chemother Pharmacol; 2005 Jun; 55(6):541-51. PubMed ID: 15729584
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate.
Nakajima Y; Iigo M; Hoshi A
Anticancer Drugs; 1992 Jun; 3(3):289-92. PubMed ID: 1525410
[TBL] [Abstract][Full Text] [Related]
20. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.
Tsukamoto Y; Kato Y; Ura M; Horii I; Ishikawa T; Ishitsuka H; Sugiyama Y
Biopharm Drug Dispos; 2001 Jan; 22(1):1-14. PubMed ID: 11745902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
